期刊文献+

Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer 被引量:19

Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer
下载PDF
导出
摘要 AIM:To investigate M2 isoform of pyruvate kinase(PKM2) expression in gastric cancers and evaluate its potential as a prognostic biomarker and an anticancer target.METHODS:All tissue samples were derived from gastric cancer patients underwent curative gastrectomy as a primary treatment.Clinical and pathological information were obtained from the medical records.Gene expression microarray data from 60 cancer and 19 noncancer gastric tissues were analyzed to evaluate the expression level of PKM2 mRNA.Tissue microarrays were constructed from 368 gastric cancer patients.Immunohistochemistry was used to measure PKM2 expression and PKM2 positivity of cancer was determined by proportion of PKM2-positive tumor cells and staining intensity.Association between PKM2 expression and the clinicopathological factors was evaluated and the correlation between PKM2 and cancer prognosis was evaluated.RESULTS:PKM2 mRNA levels were increased more than 2-fold in primary gastric cancers compared to adjacent normal tissues from the same patients(log transformed expression level:7.6 ± 0.65 vs 6.3 ± 0.51,P < 0.001).Moreover,differentiated type cancers had significantly higher PKM2 mRNA compared to undifferentiated type cancers(log transformed expression level:7.8 ± 0.70 vs 6.7 ± 0.71,P < 0.001).PKM2 protein was mainly localized in the cytoplasm of primary cancer cells and detected in 144 of 368(39.1%) human gastric cancer cases.PKM2 expression was not related with stage(P = 0.811),but strongly correlated with gastric cancer differentiation(P < 0.001).Differentiated type cancers expressed more PKM2 protein than did the undifferentiated ones.Well differentiated adenocarcinoma showed 63.6% PKM2-positive cells;in contrast,signet-ring cell cancers showed only 17.7% PKM2-positive cells.Importantly,PKM2 expression was correlated with shorter overall survival(P < 0.05) independent of stage only in signet-ring cell cancers.CONCLUSION:PKM2 expression might be an adverse prognostic factor for signet-ring cell carcinomas.Its function and potential as a prognostic marker should be further verified in gastric cancer. AIM:To investigate M2 isoform of pyruvate kinase(PKM2) expression in gastric cancers and evaluate its potential as a prognostic biomarker and an anticancer target.METHODS:All tissue samples were derived from gastric cancer patients underwent curative gastrectomy as a primary treatment.Clinical and pathological information were obtained from the medical records.Gene expression microarray data from 60 cancer and 19 noncancer gastric tissues were analyzed to evaluate the expression level of PKM2 mRNA.Tissue microarrays were constructed from 368 gastric cancer patients.Immunohistochemistry was used to measure PKM2 expression and PKM2 positivity of cancer was determined by proportion of PKM2-positive tumor cells and staining intensity.Association between PKM2 expression and the clinicopathological factors was evaluated and the correlation between PKM2 and cancer prognosis was evaluated.RESULTS:PKM2 mRNA levels were increased more than 2-fold in primary gastric cancers compared to adjacent normal tissues from the same patients(log transformed expression level:7.6 ± 0.65 vs 6.3 ± 0.51,P 〈 0.001).Moreover,differentiated type cancers had significantly higher PKM2 mRNA compared to undifferentiated type cancers(log transformed expression level:7.8 ± 0.70 vs 6.7 ± 0.71,P 〈 0.001).PKM2 protein was mainly localized in the cytoplasm of primary cancer cells and detected in 144 of 368(39.1%) human gastric cancer cases.PKM2 expression was not related with stage(P = 0.811),but strongly correlated with gastric cancer differentiation(P 〈 0.001).Differentiated type cancers expressed more PKM2 protein than did the undifferentiated ones.Well differentiated adenocarcinoma showed 63.6% PKM2-positive cells;in contrast,signet-ring cell cancers showed only 17.7% PKM2-positive cells.Importantly,PKM2 expression was correlated with shorter overall survival(P 〈 0.05) independent of stage only in signet-ring cell cancers.CONCLUSION:PKM2 expression might be an adverse prognostic factor for signet-ring cell carcinomas.Its function and potential as a prognostic marker should be further verified in gastric cancer.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第30期4037-4043,共7页 世界胃肠病学杂志(英文版)
基金 Supported by Faculty Research Grant of Yonsei University College of Medicine for 2011,6-2011-0113,6-2011-0146 A Faculty Research Grant of Department of Internal Medicine,Yonsei University College of Medicine for 2010 Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education,Science and Technology,No. 2010-0024248
关键词 肿瘤细胞 丙酮酸激酶 胃癌 预后 过度表达 亚型 MRNA水平 组织微阵列 Gastric cancer M2 isoform of pyruvate kinase Biomarker Signet ring cell carcinoma Prognosis
  • 相关文献

参考文献1

二级参考文献32

  • 1Oremek GM, Sapoutzis N, Kramer W, Bickeboller R, Jonas D.Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.Anticancer Res 2000; 20:5095-5098.
  • 2Roigas J, Deger S, Schroeder J, Wille A, Turk I, Brux B, Jung K,Schnorr D, Loening SA. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma. Urol Res 2003; 26.
  • 3Roigas J, Schulze G, Raytarowski S, Jung K, Schnorr D, Loenng SA. Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients. Urology A 2000; 39:554-556.
  • 4Schneider J, Velcovsky HG, Morr H, Katz N, Neu K, Eigenbrodt E. Comparison of the tumor markers tumor M2-PK, CEA,CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer.Anticancer Res 2000; 20:5053-5058.
  • 5Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G,Eigenbrodt E. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res 2002; 22(1A): 311-318.
  • 6Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.Anticancer Res 2003: 23(2A): 899-906.
  • 7Schneider J, Peltri G, Bitterlich N, Philipp M, Velcovsky HG,Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients. Clin Exp Med 2003;2:185-191.
  • 8Pottek T, Muller M, Blum T, Hartmann M. Tu-M2-PK in the blood of testicular and cubital veins in men with testicular cancer. Anticancer Res 2000; 20:5029-5033.
  • 9Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE,Wernecke KD, Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000; 20:5077-5082.
  • 10Hoopmann M, Warm M, Mallmann P, Thomas A, Gohring UJ,Schondorf T. Tumor M2 pyruvate kinase-determination in breast cancer patients receiving trastuzumab therapy. Cancer Lett 2002; 187:223-228.

共引文献21

同被引文献54

  • 1Xiao-Dong Bu, Nan Li, Xiao-Qiang Tian, Pei-Lin Huang,Li Li, Jin-Song Wang, Xiao-Jin Yu.Altered expression of MUC2 and MUC5AC in progression of colorectal carcinoma[J].World Journal of Gastroenterology,2010,16(32):4089-4094. 被引量:7
  • 2Wen Meng , Hong-Hong Zhu , Ze-Feng Xu , Shan-Rong Cai , Qi Dong , Qiang-Rong Pan , Shu Zheng , Su-Zhan Zhang.浆液 M2-pyruvate kinase : 为屏蔽的 colorectal 癌症质量的有希望的非侵略的 biomarker[J].World Journal of Gastrointestinal Oncology,2012,4(6):145-151. 被引量:9
  • 3陈士浩,施伟民.M2型丙酮酸激酶对肝癌诊断意义的进一步研究[J].中华肿瘤杂志,1993,15(4):268-271. 被引量:4
  • 4余秋波,李红梅,董艳玲,王应雄,何俊琳.自然流产患者蜕膜MMP10的表达及临床意义[J].重庆医科大学学报,2007,32(7):679-681. 被引量:2
  • 5韩丙辰,杨增明.子宫内膜蜕膜化的特征及其调节因素[J].细胞生物学杂志,2007,29(5):666-670. 被引量:10
  • 6Fabio Petrocca,Rosa Visone,Mariadele Rapazzotti Onelli,Manisha H. Shah,Milena S. Nicoloso,Ivana de Martino,Dimitrios Iliopoulos,Emanuela Pilozzi,Chang-Gong Liu,Massimo Negrini,Luigi Cavazzini,Stefano Volinia,Hansjuerg Alder,Luigi P. Ruco,Gustavo Baldassarre,Carlo M. Croce,Andrea Vecchione.E2F1-Regulated MicroRNAs Impair TGFβ-Dependent Cell-Cycle Arrest and Apoptosis in Gastric Cancer[J]. Cancer Cell . 2008 (3)
  • 7Yung-Jue Bang,Eric Van Cutsem,Andrea Feyereislova,Hyun C Chung,Lin Shen,Akira Sawaki,Florian Lordick,Atsushi Ohtsu,Yasushi Omuro,Taroh Satoh,Giuseppe Aprile,Evgeny Kulikov,Julie Hill,Michaela Lehle,Josef Rüschoff,Yoon-Koo Kang.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. The Lancet . 2010 (9742)
  • 8Florian Lordick,Yoon-Koo Kang,Hyun-Cheol Chung,Pamela Salman,Sang Cheul Oh,Gy?rgy Bodoky,Galina Kurteva,Constantin Volovat,Vladimir M Moiseyenko,Vera Gorbunova,Joon Oh Park,Akira Sawaki,Ilhan Celik,Heiko G?tte,Helena Melezínková,Markus Moehler.Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial[J].Lancet Oncology.2013(6)
  • 9Thang N. Tran,Kate Brettingham‐Moore,Cuong P. Duong,Catherine Mitchell,Nicholas J. Clemons,Wayne A. Phillips.Molecular changes in the phosphatidylinositide 3‐kinase (PI3K) pathway are common in gastric cancer[J].J Surg Oncol.2013(2)
  • 10Jeeyun Lee,Jin Seo,Hyun Jun,Chang-Seok Ki,Se Park,Young Park,Ho Lim,Min Choi,Jae Bae,Tae Sohn,Jae Noh,Sung Kim,Hey-Lim Jang,Ji-Youn Kim,Kyoung-Mee Kim,Won Kang,Joon Park.Impact of MET amplification on gastric cancer: Possible roles as a novelprognostic marker and a potential therapeutic target[J].Oncology Reports.2011(6)

引证文献19

二级引证文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部